Literature DB >> 20354930

Current trends in immunosuppression for lung transplantation.

Timothy Floreth1, Sangeeta M Bhorade.   

Abstract

Lung transplant has become an established therapy in the treatment of end-stage lung disease. Many of the advances in the modern immunosuppression regimen have provided more quality and quantity of life to transplant patients. Immunosuppression agents target various aspects of the immune system to maximize graft tolerance while minimizing medication toxicities and side effects. Lung transplant regimens follow typical protocols but are always tailored to the individual patient based upon previous and current medical problems. Despite the various advances, acute and chronic rejections still occur in the majority of all lung transplants. For these reasons, long-term lung transplantation success remains a challenge. Further improvement in immunosuppression will be geared toward minimizing rejection and infection as well as being tailored to the individual patient. This review details the current armamentarium of immunosuppression medications and the current body of evidence supporting the current trends of usage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20354930     DOI: 10.1055/s-0030-1249112

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  10 in total

1.  [Varicella gastritis under immunosuppression : Case report of a woman after lung transplantation due to granulomatosis with polyangiitis].

Authors:  S Saman; J-C Henes; D Niepel; H Bosmüller; C R Werner; U M Lauer; N P Malek; T Xenitidis
Journal:  Internist (Berl)       Date:  2017-08       Impact factor: 0.743

Review 2.  New frontiers in immunosuppression.

Authors:  Luke J Benvenuto; Michaela R Anderson; Selim M Arcasoy
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 3.  Lung transplantation: a treatment option in end-stage lung disease.

Authors:  Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

4.  Five-year outcomes with alemtuzumab induction after lung transplantation.

Authors:  Susan Shyu; Mary Amanda Dew; Joseph M Pilewski; Annette J DeVito Dabbs; Diana B Zaldonis; Sean M Studer; Maria M Crespo; Yoshiya Toyoda; Christian A Bermudez; Kenneth R McCurry
Journal:  J Heart Lung Transplant       Date:  2011-03-21       Impact factor: 10.247

5.  Long term complications following 54 consecutive lung transplants.

Authors:  Walther Tabarelli; Hugo Bonatti; Dominique Tabarelli; Miriam Eller; Ludwig Müller; Elfriede Ruttmann; Cornelia Lass-Flörl; Clara Larcher; Christian Geltner
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 6.  Psychosocial issues facing lung transplant candidates, recipients and family caregivers.

Authors:  Emily M Rosenberger; Mary Amanda Dew; Andrea F DiMartini; Annette J DeVito Dabbs; Roger D Yusen
Journal:  Thorac Surg Clin       Date:  2012-11       Impact factor: 1.750

7.  Splenocyte Infusion and Whole-Body Irradiation for Induction of Peripheral Tolerance in Porcine Lung Transplantation: Modifications of the Preconditioning Regime for Improved Clinical Feasibility.

Authors:  Katharina Jansson; Karla Dreckmann; Wiebke Sommer; Murat Avsar; Jawad Salman; Thierry Siemeni; Ann-Kathrin Knöfel; Linda Pauksch; Jens Gottlieb; Jörg Frühauf; Martin Werner; Danny Jonigk; Martin Strüber; Axel Haverich; Gregor Warnecke
Journal:  Transplant Direct       Date:  2017-06-06

8.  Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation.

Authors:  Juliessa Florian; Guilherme Watte; Paulo José Zimermann Teixeira; Stephan Altmayer; Sadi Marcelo Schio; Letícia Beatriz Sanchez; Douglas Zaione Nascimento; Spencer Marcantonio Camargo; Fabiola Adélia Perin; José de Jesus Camargo; José Carlos Felicetti; José da Silva Moreira
Journal:  Sci Rep       Date:  2019-06-27       Impact factor: 4.379

Review 9.  Lung transplant infection.

Authors:  Sergio R Burguete; Diego J Maselli; Juan F Fernandez; Stephanie M Levine
Journal:  Respirology       Date:  2013-01       Impact factor: 6.424

10.  Alemtuzumab induction combined with reduced maintenance immunosuppression is associated with improved outcomes after lung transplantation: A single centre experience.

Authors:  Alberto Benazzo; Stefan Schwarz; Moritz Muckenhuber; Thomas Schweiger; Gabriela Muraközy; Bernhard Moser; José Matilla Sigüenza; György Lang; Shahrokh Taghavi; Walter Klepetko; Konrad Hoetzenecker; Peter Jaksch; Cristopher Lambers
Journal:  PLoS One       Date:  2019-01-15       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.